Top

Published in:

Open Access 01-12-2011 | Review

Current views on the role of Notch signaling and the pathogenesis of human leukemia

Authors: Joanna Pancewicz, Christophe Nicot

Published in: BMC Cancer | Issue 1/2011

Abstract

The Notch signaling pathway is highly conserved from Drosophila to humans and plays an important role in the regulation of cellular proliferation, differentiation and apoptosis.

Constitutive activation of Notch signaling has been shown to result in excessive cellular proliferation and a wide range of malignancies, including leukemia, glioblastoma and lung and breast cancers. Notch can also act as a tumor suppressor, and its inactivation has been associated with an increased risk of spontaneous squamous cell carcinoma. This minireview focuses on recent advances related to the mechanisms and roles of activated Notch1, Notch2, Notch3 and Notch4 signaling in human lymphocytic leukemia, myeloid leukemia and B cell lymphoma, as well as their significance, and recent advances in Notch-targeted therapies.

Available only for authorised users

D'Souza B, Meloty-Kapella L, Weinmaster G: Canonical and non-canonical Notch ligands. Curr Top Dev Biol. 2010, 92: 73-129.CrossRefPubMedPubMedCentral

Kovall RA, Blacklow SC: Mechanistic insights into Notch receptor signaling from structural and biochemical studies. Curr Top Dev Biol. 2010, 92: 31-71.CrossRefPubMed

Kopan R, Ilagan MXG: The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009, 137: 216-233. 10.1016/j.cell.2009.03.045.CrossRefPubMedPubMedCentral

Bray S, Bernard F: Notch targets and their regulation. Curr Top Dev Biol. 2010, 92: 253-275.CrossRefPubMed

Fortini ME: Notch signaling: the core pathway and its posttranslational regulation. Dev Cell. 2009, 16: 633-647. 10.1016/j.devcel.2009.03.010.CrossRefPubMed

Chastagner P, Israël A, Brou C: AIP4/Itch regulates Notch receptor degradation in the absence of ligand. PLoS One. 2008, 3: e2735-10.1371/journal.pone.0002735.CrossRefPubMedPubMedCentral

Wilkin MB, Carbery AM, Fostier M, Aslam H, Mazaleyrat SL, Higgs J, Myat A, Evans DAP, Cornell M, Baron M: Regulation of Notch endosomal sorting and signaling by Drosophila Nedd4 family proteins. Curr Biol. 2004, 14: 2237-2244. 10.1016/j.cub.2004.11.030.CrossRefPubMed

McGill MA, McGlade CJ: Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J Biol Chem. 2003, 278: 23196-23203. 10.1074/jbc.M302827200.CrossRefPubMed

Fortini ME, Bilder D: Endocytic regulation of Notch signaling. Curr Opin Genet Dev. 2009, 19: 323-328. 10.1016/j.gde.2009.04.005.CrossRefPubMedPubMedCentral

10.

Welcker M, Clurman BE: FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2008, 8: 83-93. 10.1038/nrc2290.CrossRefPubMed

11.

del Álamo D, Rouault H, Schweisguth F: Mechanism and significance of cis-inhibition in Notch signalling. Curr Biol. 2011, 21: R40-R47. 10.1016/j.cub.2010.10.034.CrossRefPubMed

12.

Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT: Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003, 425: 841-846. 10.1038/nature02040.CrossRefPubMed

13.

Maillard I, Adler SH, Pear WS: Notch and the immune system. Immunity. 2003, 19: 781-791. 10.1016/S1074-7613(03)00325-X.CrossRefPubMed

14.

Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J: TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991, 66: 649-661. 10.1016/0092-8674(91)90111-B.CrossRefPubMed

15.

Reynolds TC, Smith SD, Sklar J: Analysis of DNA surrounding the breakpoints of chromosomal translocations involving the β T cell receptor gene in human lymphoblastic neoplasms. Cell. 1987, 50: 107-117. 10.1016/0092-8674(87)90667-2.CrossRefPubMed

16.

Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004, 306: 269-271. 10.1126/science.1102160.CrossRefPubMed

17.

Pancewicz J, Taylor JM, Datta A, Baydoun HH, Waldmann TA, Hermine O, Nicot C: Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci USA. 2010, 107: 16619-16624. 10.1073/pnas.1010722107.CrossRefPubMedPubMedCentral

18.

Sulis ML, Williams O, Palomero T, Tosello V, Pallikuppam S, Real PJ, Barnes K, Zuurbier L, Meijerink JP, Ferrando AA: NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood. 2008, 112: 733-740. 10.1182/blood-2007-12-130096.CrossRefPubMedPubMedCentral

19.

O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, Hardwick J, Welcker M, Meijerink JP, Pieters R, Draetta G, Sears R, Clurman BE, Look AT: FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors. J Exp Med. 2007, 204: 1813-1824. 10.1084/jem.20070876.CrossRefPubMedPubMedCentral

20.

Jin YH, Kim H, Ki H, Yang I, Yang N, Lee KY, Kim N, Park HS, Kim K: β-catenin modulates the level and transcriptional activity of Notch1/NICD through its direct interaction. Biochim Biophys Acta. 2009, 1793: 290-299. 10.1016/j.bbamcr.2008.10.002.CrossRefPubMed

21.

Erbilgin Y, Sayitoglu M, Hatirnaz O, Dogru O, Akcay A, Tuysuz G, Celkan T, Aydogan G, Salcioglu Z, Timur C, Yuksel-Soycan L, Ure U, Anak S, Agaoglu L, Devecioglu O, Yildiz I, Ozbek U: Prognostic significance of NOTCH1 and FBXW7 mutations in pediatric T-ALL. Dis Markers. 2010, 28: 353-360.CrossRefPubMedPubMedCentral

22.

Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Koo K, Allen CG, Gale RE, Buck G, Richards S, Paietta E, Rowe JM, Tallman MS, Goldstone AH, Ferrando AA, Linch DC: Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol. 2009, 27: 4352-4356. 10.1200/JCO.2009.22.0996.CrossRefPubMedPubMedCentral

23.

Allenspach EJ, Maillard I, Aster JC, Pear WS: Notch signaling in cancer. Cancer Biol Ther. 2002, 1: 466-476. 10.4161/cbt.1.5.162.CrossRefPubMed

24.

Paganin M, Ferrando A: Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev. 2011, 25: 83-90. 10.1016/j.blre.2010.09.004.CrossRefPubMed

25.

Zweidler-McKay PA: Notch signaling in pediatric malignancies. Curr Oncol Rep. 2008, 10: 459-468. 10.1007/s11912-008-0071-2.CrossRefPubMed

26.

Radtke F, Fasnacht N, MacDonald HR: Notch signaling in the immune system. Immunity. 2010, 32: 14-27. 10.1016/j.immuni.2010.01.004.CrossRefPubMed

27.

Mansour MR, Duke V, Foroni L, Patel B, Allen CG, Ancliff PJ, Gale RE, Linch DC: Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2007, 13: 6964-6969. 10.1158/1078-0432.CCR-07-1474.CrossRefPubMed

28.

Eguchi-Ishimae M, Eguchi M, Kempski H, Greaves M: NOTCH1 mutation can be an early, prenatal genetic event in T-ALL. Blood. 2008, 111: 376-378. 10.1182/blood-2007-02-074690.CrossRefPubMed

29.

Rohn JL, Lauring AS, Linenberger ML, Overbaugh J: Transduction of Notch2 in feline leukemia virus-induced thymic lymphoma. J Virol. 1996, 70: 8071-8080.PubMedPubMedCentral

30.

Witt CM, Hurez V, Swindle CS, Hamada Y, Klug CA: Activated Notch2 potentiates CD8 lineage maturation and promotes the selective development of B1 B cells. Mol Cell Biol. 2003, 23: 8637-8650. 10.1128/MCB.23.23.8637-8650.2003.CrossRefPubMed

31.

Lee S, Kumano K, Nakazaki K, Sanada M, Matsumoto A, Yamamoto G, Nannya Y, Suzuki R, Ota S, Ota Y, Izutsu K, Sakata-Yanagimoto M, Hangaishi A, Yagita H, Fukayama M, Seto M, Kurokawa M, Ogawa S, Chiba S: Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci. 2009, 100: 920-926. 10.1111/j.1349-7006.2009.01130.x.CrossRefPubMed

32.

Trøen G, Wlodarska I, Warsame A, Hernández Llodrà S, De Wolf-Peeters C, Delabie J: NOTCH2 mutations in marginal zone lymphoma. Haematologica. 2008, 93: 1107-1109. 10.3324/haematol.11635.CrossRefPubMed

33.

Hubmann R, Düchler M, Schnabl S, Hilgarth M, Demirtas D, Mitteregger D, Hölbl A, Vanura K, Le T, Look T, Schwarzmeier JD, Valent P, Jäger U, Shehata M: NOTCH2 links protein kinase C δ to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. Br J Haematol. 2010, 148: 868-878. 10.1111/j.1365-2141.2009.08024.x.CrossRefPubMed

34.

Hubmann R, Schwarzmeier JD, Shehata M, Hilgarth M, Duechler M, Dettke M, Berger R: Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood. 2002, 99: 3742-3747. 10.1182/blood.V99.10.3742.CrossRefPubMed

35.

Bellavia D, Campese AF, Checquolo S, Balestri A, Biondi A, Cazzaniga G, Lendahl U, Fehling HJ, Hayday AC, Frati L, von Boehmer H, Gulino A, Screpanti I: Combined expression of pTα and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci USA. 2002, 99: 3788-3793. 10.1073/pnas.062050599.CrossRefPubMedPubMedCentral

36.

Asnafi V, Beldjord K, Boulanger E, Comba B, Le Tutour P, Estienne MH, Davi F, Landman-Parker J, Quartier P, Buzyn A, Delabesse E, Valensi F, Macintyre E: Analysis of TCR, pTα, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood. 2003, 101: 2693-2703. 10.1182/blood-2002-08-2438.CrossRefPubMed

37.

Checquolo S, Palermo R, Cialfi S, Ferrara G, Oliviero C, Talora C, Bellavia D, Giovenco A, Grazioli P, Frati L, Gulino A, Screpanti I: Differential subcellular localization regulates c-Cbl E3 ligase activity upon Notch3 protein in T-cell leukemia. Oncogene. 2010, 29: 1463-1474. 10.1038/onc.2009.446.CrossRefPubMed

38.

Bellavia D, Campese AF, Alesse E, Vacca A, Felli MP, Balestri A, Stoppacciaro A, Tiveron C, Tatangelo L, Giovarelli M, Gaetano C, Ruco L, Hoffman ES, Hayday AC, Lendahl U, Frati L, Gulino A, Screpanti I: Constitutive activation of NF-κΒ and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J. 2000, 19: 3337-3348. 10.1093/emboj/19.13.3337.CrossRefPubMedPubMedCentral

39.

Masiero M, Minuzzo S, Pusceddu I, Moserle L, Persano L, Agnusdei V, Tosello V, Basso G, Amadori A, Indraccolo S: Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells. Leukemia. 2011, 25: 588-598. 10.1038/leu.2010.323.CrossRefPubMed

40.

Karanu FN, Yuefei L, Gallacher L, Sakano S, Bhatia M: Differential response of primitive human. Leukemia. 2003, 17: 1366-1374. 10.1038/sj.leu.2402973.CrossRefPubMed

41.

Vercauteren SM, Sutherland HJ: Constitutively active Notch4 promotes early human hematopoietic progenitor cell maintenance while inhibiting differentiation and causes lymphoid abnormalities in vivo. Blood. 2004, 104: 2315-2322. 10.1182/blood-2004-01-0204.CrossRefPubMed

42.

Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A, Tsaparikos K, Jani JP, Hosea N, Sands M, Randolph S, Smeal T: Evaluation of selective γ-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther. 2010, 9: 1618-1628. 10.1158/1535-7163.MCT-10-0034.CrossRefPubMed

43.

Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, Roberts J, Cai J, Berkofsky-Fessler W, Hilton H, Linn M, Flohr A, Jakob-Røtne R, Jacobsen H, Glenn K, Heimbrook D, Boylan JF: Preclinical profile of a potent γ-secretase inhibitor targeting Notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res. 2009, 69: 7672-7680. 10.1158/0008-5472.CAN-09-1843.CrossRefPubMed

44.

He W, Luistro L, Carvajal D, Smith M, Nevins T, Yin X, Cai J, Higgins B, Kolinsky K, Rizzo C, Packman K, Heimbrook D, Boylan JF: High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097. Mol Oncol. 2011, 5: 292-301. 10.1016/j.molonc.2011.01.001.CrossRefPubMed

45.

Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, Bhagat G, Agarwal AM, Basso G, Castillo M, Nagase S, Cordon-Cardo C, Parsons R, Zúñiga-Pflücker JC, Dominguez M, Ferrando AA: Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007, 13: 1203-1210. 10.1038/nm1636.CrossRefPubMedPubMedCentral

46.

Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, Finkle D, Venook R, Wu X, Ridgway J, Schahin-Reed D, Dow GJ, Shelton A, Stawicki S, Watts RJ, Zhang J, Choy R, Howard P, Kadyk L, Yan M, Zha J, Callahan CA, Hymowitz SG, Siebel CW: Therapeutic antibody targeting of individual Notch receptors. Nature. 2010, 464: 1052-1057. 10.1038/nature08878.CrossRefPubMed

47.

Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, Kung AL, Gilliland DG, Verdine GL, Bradner JE: Direct inhibition of the NOTCH transcription factor complex. Nature. 2009, 462: 182-188. 10.1038/nature08543.CrossRefPubMedPubMedCentral

48.

Clappier E, Collette S, Grardel N, Girard S, Suarez L, Brunie G, Kaltenbach S, Yakouben K, Mazingue F, Robert A, Boutard P, Plantaz D, Rohrlich P, van Vlierberghe P, Preudhomme C, Otten J, Speleman F, Dastugue N, Suciu S, Benoit Y, Bertrand Y, Cavé H, EORTC-CLG: NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia. 2010, 24: 2023-2031. 10.1038/leu.2010.205.CrossRefPubMed

49.

Park MJ, Taki T, Oda M, Watanabe T, Yumura-Yagi K, Kobayashi R, Suzuki N, Hara J, Horibe K, Hayashi Y: FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol. 2009, 145: 198-206. 10.1111/j.1365-2141.2009.07607.x.CrossRefPubMed

50.

Sportoletti P, Baldoni S, Cavalli L, Del Papa B, Bonifacio E, Ciurnelli R, Bell AS, Di Tommaso A, Rosati E, Crescenzi B, Mecucci C, Screpanti I, Marconi P, Martelli MF, Di Iannini M, Falzetti F: NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br J Haematol. 2010, 151: 404-406. 10.1111/j.1365-2141.2010.08368.x.CrossRefPubMed

51.

Di Ianni M, Baldoni S, Rosati E, Ciurnelli R, Cavalli L, Martelli MF, Marconi P, Screpanti I, Falzetti F: A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol. 2009, 146: 689-691. 10.1111/j.1365-2141.2009.07816.x.CrossRefPubMed

52.

Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, Escaramis G, Jares P, Beà S, González-Díaz M, Bassaganyas L, Baumann T, Juan M, López-Guerra M, Colomer D, Tubío JM, López C, Navarro A, Tornador C, Aymerich M, Rozman M, Hernández JM, Puente DA, Freije JM, Velasco G, Gutiérrez-Fernández A, Costa D, Carrió A, Guijarro S, Enjuanes A, et al: Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011, 475: 101-105. 10.1038/nature10113.CrossRefPubMedPubMedCentral

53.

Fu L, Kogoshi H, Nara N, Tohda S: NOTCH1 mutations are rare in acute myeloid leukemia. Leuk Lymphoma. 2006, 47: 2400-2403. 10.1080/10428190600773339.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/502/prepub

Title: Current views on the role of Notch signaling and the pathogenesis of human leukemia
Authors: Joanna Pancewicz
Christophe Nicot
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-11-502

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Notch signaling contributes to the maintenance of both normal neural stem cells and patient-derived glioma stem cells

Primary leiomyosarcoma of the seminal vesicle: Case report and review of the literature

Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review

Support vector machine model for diagnosis of lymph node metastasis in gastric cancer with multidetector computed tomography: a preliminary study

Identification and Regulation of c-Myb Target Genes in MCF-7 Cells

The prognostic effect of ethnicity for gastric and esophageal cancer: the population-based experience in British Columbia, Canada

Keynote webinar | Spotlight on antibody–drug conjugates in cancer